Where Will CTI BioPharma Corp (CTIC) Stock Go Next After It Has Risen 4.89% in a Week?

Monday, August 08, 2022 10:20 AM | InvestorsObserver Analysts

Mentioned in this article

Where Will CTI BioPharma Corp (CTIC) Stock Go Next After It Has Risen 4.89% in a Week?

CTI BioPharma Corp (CTIC) stock is up 4.89% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

CTI BioPharma Corp has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CTIC!

See Full CTIC Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With CTIC Stock Today?

CTI BioPharma Corp (CTIC) stock is down -1.88% while the S&P 500 has risen 0.82% as of 10:15 AM on Monday, Aug 8. CTIC is lower by -$0.14 from the previous closing price of $7.43 on volume of 748,655 shares. Over the past year the S&P 500 is lower by -5.71% while CTIC has risen 144.63%. CTIC lost -$1.22 per share in the over the last 12 months.

More About CTI BioPharma Corp

CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. Its therapeutic area is blood-related cancers. Its products under pipeline include PIXUVRI, and Pacritinib. PIXUVRI is a novel aza-anthracenedione with unique structural and physiochemical properties. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis. Click Here to get the full Stock Report for CTI BioPharma Corp stock.